BridgeBio looks to fully own its CV subsidiary Eidos

BridgeBio looks to fully own its CV subsidiary Eidos

Source: 
BioCentury
snippet: 

BridgeBio fell $2.94 (10%) to $26.88 Friday after proposing Thursday to fully acquire its cardiovascular-focused subsidiary Eidos, which climbed $3.11 (10%) to $35.17 on the news.